Welcome to our dedicated page for MoonLake Immunotherapeutics news (Ticker: MLTX), a resource for investors and traders seeking the latest updates and insights on MoonLake Immunotherapeutics stock.
MoonLake Immunotherapeutics (symbol: MLTX) is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for immunologic diseases, particularly inflammatory skin and joint conditions. Leveraging its cutting-edge Nanobody® technology, MoonLake aims to create next-level medicines that offer significant improvements over existing therapies.
The company’s flagship product, Sonelokimab, is currently in clinical trials and has shown promising results in treating chronic inflammatory diseases. MoonLake's ARGO trial is a key initiative evaluating the efficacy and safety of Sonelokimab in patients with these debilitating conditions.
Headquartered in the United Kingdom, MoonLake generates the majority of its revenue from this market. The company’s recent Third Quarter 2023 Financial Highlights reflect robust progress, with important upcoming events and clinical data releases anticipated. Additionally, MoonLake’s extensive partnership with healthcare technology platform Komodo Health facilitates the use of real-world data to optimize their drug development processes.
Investors and stakeholders can look forward to MoonLake’s Fourth Quarter and Year-End Financial Results as well as the R&D Day on March 10. These events are expected to provide deeper insights into the company’s ongoing projects and future outlook. With a focus on creating value-driven healthcare solutions, MoonLake is positioned to make significant contributions to the field of immunotherapeutics.
For the latest updates and detailed information, stakeholders are encouraged to follow MoonLake’s news releases and financial disclosures. The company also engages actively in upcoming banking conferences, which provide platforms to discuss their innovative approaches and upcoming milestones.
ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (Nasdaq: MLTX) is hosting its Capital Markets Day in New York, featuring a live webcast for virtual attendees. The event runs from 10:30-12:30 EDT and includes presentations from the executive team discussing a financial update, near-term catalysts, and the company’s publication roadmap.
The focus will be on sonelokimab, a novel investigational Nanobody® targeting inflammatory diseases, along with an update from Professor Kenneth B. Gordon on treatment landscapes following the AAD Annual Meeting. Top-line results for sonelokimab’s Phase 2 trial in hidradenitis suppurativa are anticipated by June 2023, with additional trials in psoriatic arthritis ongoing.
MoonLake Immunotherapeutics (NASDAQ:MLTX) reported its Q4 and year-end financial results for 2022, revealing a strong cash position of $72.1 million, providing operational runway into 2H 2024.
The company has completed patient enrollment ahead of schedule in its global Phase 2 trial of sonelokimab for Hidradenitis Suppurativa, with top-line results expected by June 2023. Additionally, enrollment for the Psoriatic Arthritis trial is ongoing and on schedule, with results anticipated by year-end. The net loss for the year was $64.5 million, an increase from $53.6 million in the prior period. The CEO highlighted the successful initiation of clinical trials and competitive positioning in the IL-17 inhibitor market.
MoonLake Immunotherapeutics announced the completion of patient enrollment and randomization ahead of schedule for its Phase 2 clinical trial of sonelokimab in treating moderate-to-severe hidradenitis suppurativa (HS). The trial, known as the MIRA trial, has reached its target of 210 patients and aims to evaluate the effectiveness of sonelokimab, a novel IL-17A and IL-17F inhibitor. Top-line results are expected by mid-2023, with a final readout planned for Q4 2023. The trial uses HiSCR75 as its primary endpoint, reflecting MoonLake's ambition to improve patient outcomes.
MoonLake Immunotherapeutics has initiated a Phase 2 study named ARGO for sonelokimab, targeting active psoriatic arthritis.
The randomized, double-blind trial involves approximately 200 patients to evaluate the drug's efficacy and safety against a placebo and adalimumab.
The primary endpoint is the ACR 50 response, measuring ≥50% improvement in disease symptoms. This follows successful results from a Phase 2b study in psoriasis, highlighting sonelokimab's potential in treating inflammatory conditions.
MoonLake Immunotherapeutics (NASDAQ:MLTX) reported its Q3 2022 financial results, highlighting a cash position of $83.5 million, providing a runway into 2H 2024. The global trial of sonelokimab for Hidradenitis Suppurativa continues to meet recruitment goals, with primary endpoint data expected mid-2023. Additionally, the Psoriatic Arthritis trial received FDA clearance and is on schedule. R&D expenses decreased to $9 million from $11.4 million, while the net loss narrowed to $14.7 million compared to the previous quarter.
FAQ
What is the current stock price of MoonLake Immunotherapeutics (MLTX)?
What is the market cap of MoonLake Immunotherapeutics (MLTX)?
What does MoonLake Immunotherapeutics specialize in?
What is Sonelokimab?
Where is MoonLake Immunotherapeutics headquartered?
What is the ARGO trial?
What are MoonLake’s most recent financial highlights?
When are MoonLake’s Fourth Quarter and Year-End Financial Results expected?
What role does Komodo Health play in MoonLake’s operations?
How can I stay updated on MoonLake’s latest news?
What are some of the upcoming events for MoonLake?
How can I contact MoonLake Immunotherapeutics?
